Erratum to “Virtual mutation and directional evolution of anti-amoxicillin ScFv antibody for immunoassay of penicillins in milk” [Anal. Biochem. 517 (2017) 9–17]

Q4 · BIOLOGY

Article

Author: Dong, Jun ; Liu, Jing ; Qi, Yong Hua ; Zhao, Guo Xian ; Wang, Geng Nan ; He, Xin ; Duan, Chang Fei ; Wang, Jian Ping

Two panels from Fig. 3, C and F, were omitted.The corrected figure is provided.

01 Apr 2017·Nuclear Medicine and BiologyQ4 · MEDICINE

PET imaging of 64Cu-DOTA-scFv-anti-PSMA lipid nanoparticles (LNPs): Enhanced tumor targeting over anti-PSMA scFv or untargeted LNPs

Q4 · MEDICINE

Article

Author: Li, Lin ; Crow, Desiree ; Wong, Patty ; Colcher, David ; Chea, Junie ; Bowles, Nicole ; Yazaki, Paul J ; Delgado, Melissa K ; Wong, Jeffrey Y C ; Channappa, Divya ; Poku, Erasmus ; Shively, John E ; Szpikowska, Barbara

INTRODUCTIONSingle chain (scFv) antibodies are ideal targeting ligands due to their modular structure, high antigen specificity and affinity. These monovalent ligands display rapid tumor targeting but have limitations due to their fast urinary clearance.METHODSAn anti-prostate membrane antigen (PSMA) scFv with a site-specific cysteine was expressed and evaluated in a prostate cancer xenograft model by Cu-64 PET imaging. To enhance tumor accumulation, the scFv-cys was conjugated to the co-polymer DSPE-PEG-maleimide that spontaneously assembled into a homogeneous multivalent lipid nanoparticle (LNP).RESULTSThe targeted LNP exhibited a 2-fold increase in tumor uptake compared to the scFv alone using two different thiol ester chemistries. The anti-PSMA scFv-LNP exhibited a 1.6 fold increase in tumor targeting over the untargeted LNP.CONCLUSIONSThe targeted anti-PSMA scFv-LNP showed enhanced tumor accumulation over the scFv alone or the untargeted DOTA-micelle providing evidence for the development of this system for drug delivery.ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CAREAnti-tumor scFv antibody fragments have not achieved their therapeutic potential due to their fast blood clearance. Conjugation to an LNP enables multivalency to the tumor antigen as well as increased molecular size for chemotherapy drug delivery.

01 Jan 2017·Analytical BiochemistryQ4 · BIOLOGY

Virtual mutation and directional evolution of anti-amoxicillin ScFv antibody for immunoassay of penicillins in milk

Q4 · BIOLOGY

Article

Author: Dong, Jun ; Liu, Jing ; Qi, Yong Hua ; Wang, Geng Nan ; Zhao, Guo Xian ; Duan, Chang Fei ; He, Xin ; Wang, Jian Ping

In this study, an anti-amoxicillin single chain variable fragment (ScFv) antibody was evolved by directional mutagenesis of a contact amino acid residue based on the analysis of virtual mutation. Comparison with its parental ScFv, the mutant showed highly improved affinity for 11 penicillins with up to 6-folds increased sensitivity. Then, its recognition mechanisms for the 11 drugs were studied by using molecular docking. Results showed that the mutant-penicillins intermolecular forces increased and the total binding energies decreased dramatically, which were responsible for the improvement of antibody sensitivity. The ScFv mutant was used to develop an indirect competitive enzyme linked immunosorbent assay for determination of the 11 drugs in milk. The limits of detection were in the range of 0.2-3.0 ng/mL, the crossreactivities were in the range of 31%-132%, and the recoveries from standards fortified blank milk were in the range of 65.7%-92.4%. This is the first study reporting the directional evolution of a ScFv antibody based on virtual mutation and the use of ScFv antibody for determination of penicillins in foods of animal origin.

100 Deals associated with TE-4132

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sepsis	Discovery	TW	Immunwork, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

TE-4132

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation